Robert Blaustein, M.D., Ph.D.

 - is the Chief Development Officer at Edgewise Therapeutics. Prior to this role he was an Associate Vice President at Merck, and the Atherosclerosis Section Head in the Atherosclerosis and Metabolism Clinical Research Department, leading all late phase development efforts in the Atherosclerosis space. During his 15+ years at Merck Dr. Blaustein contributed to clinical programs across a range of cardiovascular targets and led clinical development in the atherosclerosis and heart failure spaces. Dr. Blaustein obtained his undergraduate degree in mathematics from Wesleyan University. His post-graduate training included a medical residency at Brigham and Women’s Hospital, cardiology fellowship training at Massachusetts General Hospital, and a post-doctoral fellowship in the lab of Chris Miller, an HHMI investigator in the Biochemistry Department at Brandeis University. He then joined the faculty of Tufts Medical Center running an R01-funded laboratory studying ion channel proteins. At Tufts he also served as an attending cardiologist in the Cardiology Division, was a faculty member in the Neuroscience and Biochemistry Departments and was co-director of the medical school's MD-PhD Medical Scientist Training Program.